Emilio Minatel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10193632/publications.pdf

Version: 2024-02-01

68 papers 1,365

430442 18 h-index 36 g-index

68 all docs 68
docs citations

68 times ranked 1547 citing authors

#	Article	IF	CITATIONS
1	Radical Hemithoracic Radiotherapy Versus Palliative Radiotherapy in Non-metastatic Malignant Pleural Mesothelioma: Results from a Phase 3 Randomized Clinical Trial. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1368-1376.	0.4	13
2	Radical Hemithoracic Radiotherapy Induces Systemic Metabolomics Changes That Are Associated with the Clinical Outcome of Malignant Pleural Mesothelioma Patients. Cancers, 2021, 13, 508.	1.7	4
3	Prognostic Nutritional Index Predicts Toxicity in Head and Neck Cancer Patients Treated with Definitive Radiotherapy in Association with Chemotherapy. Nutrients, 2021, 13, 1277.	1.7	23
4	Biological Pathways Associated With the Development of Pulmonary Toxicities in Mesothelioma Patients Treated With Radical Hemithoracic Radiation Therapy: A Preliminary Study. Frontiers in Oncology, 2021, 11, 784081.	1.3	3
5	Prognostic significance of neutrophilâ€toâ€lymphocyte ratio in HPV status era for oropharyngeal cancer. Oral Diseases, 2020, 26, 1384-1392.	1.5	15
6	PO-063 Induction chemotherapy followed by radiotherapy for organ preservation in Oropharyngeal Cancer. Radiotherapy and Oncology, 2019, 132, 33-34.	0.3	О
7	PO-065 Do comorbidities affect survival in head and neck cancer treated with Cetuximab and Radiotherapy?. Radiotherapy and Oncology, 2019, 132, 34-35.	0.3	0
8	PO-164 Regional nodal failure after primary treatment for differentiated thyroid cancer. Radiotherapy and Oncology, 2019, 132, 87.	0.3	O
9	OC-0500 Radical Hemi-thoracic Radiotherapy vs. Palliative Radiotherapy for Malignant Pleural Mesothelioma Radiotherapy and Oncology, 2019, 133, S257.	0.3	5
10	Predictive Value of Dosimetric Measures on Lung Toxicity in Randomized Trial of Radical RT with Intact Lung in Malignant Pleural Mesothelioma. International Journal of Radiation Oncology Biology Physics, 2019, 105, E490.	0.4	0
11	EP-1143 Regional nodal failure after primary treatment for differentiated thyroid cancer Radiotherapy and Oncology, 2019, 133, S634-S635.	0.3	O
12	Direct health-care cost of head and neck cancers: a population-based study in north-eastern Italy. Medical Oncology, 2019, 36, 31.	1.2	11
13	Radiotherapy for Pleural Mesothelioma. , 2019, , 147-164.		O
14	The impact of time to treatment initiation on survival from head and neck cancer in north-eastern Italy. Oral Oncology, 2017, 67, 175-182.	0.8	50
15	Voxel-by-voxel correlation between radiologically radiation induced lung injury and dose after image-guided, intensity modulated radiotherapy for lung tumors. Physica Medica, 2017, 42, 150-156.	0.4	22
16	EP-1088: Is time from symptom to treatment a prognostic factor in stage III-IV head and neck cancer patients?. Radiotherapy and Oncology, 2016, 119, S523-S524.	0.3	0
17	Stereotactic body radiation therapy and intensity modulated radiation therapy induce different plasmatic cytokine changes in non-small cell lung cancer patients: a pilot study. Clinical and Translational Oncology, 2016, 18, 1003-1010.	1.2	15
18	Radical Radiation Therapy After Lung Sparing Surgery for Malignant Pleural Mesothelioma: Survival, Pattern of Failure, and Prognostic Factors. International Journal of Radiation Oncology Biology Physics, 2015, 93, S187-S188.	0.4	0

#	Article	IF	CITATIONS
19	Normal tissue complication probability models for severe acute radiological lung injury after radiotherapy for lung cancer. Physica Medica, 2015, 31, 1-8.	0.4	26
20	Radical Radiation Therapy After Lung-Sparing Surgery for Malignant Pleural Mesothelioma: Survival, Pattern of Failure, and Prognostic Factors. International Journal of Radiation Oncology Biology Physics, 2015, 93, 606-613.	0.4	42
21	Cell-free DNA as a prognostic marker in stage I non-small-cell lung cancer patients undergoing stereotactic body radiotherapy. Biomarkers, 2015, 20, 422-428.	0.9	17
22	Intensity-Modulated Radiotherapy with a Simultaneous Integrated Boost Combined with Chemotherapy in Stages III-IV Hypopharynx-Larynx Cancer: Treatment Compliance and Clinical Outcomes. Journal of Radiotherapy, 2014, 2014, 1-7.	0.2	1
23	IMRT with concomitant boost versus conventional radiation in the setting of sequential chemoradiotherapy for oropharyngeal cancer. Journal of Radiotherapy in Practice, 2014, 13, 418-427.	0.2	0
24	SBRT for Re-irradiation of Persistent or Recurrent Locally Advanced NSCLC. International Journal of Radiation Oncology Biology Physics, 2014, 90, S606.	0.4	0
25	Extended Pleurectomy/Decortication or Surgical Biopsy in the Era of High Doses of Radiation Therapy for Malignant Pleural Mesothelioma. International Journal of Radiation Oncology Biology Physics, 2014, 90, S638.	0.4	0
26	Multiplexed Plasma Cytokine Chemokine and Growth Factor Profiling in Early-Stage Non-Small Cell Lung Cancer Patients Undergoing Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 90, S811-S812.	0.4	1
27	Stereotactic Body Radiation Therapy for Re-irradiation of Persistent or Recurrent Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1114-1119.	0.4	79
28	Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up. Lung Cancer, 2014, 83, 78-82.	0.9	76
29	Radical Pleurectomy/Decortication Followed by High Dose of Radiation Therapy Delivered With Tomotherapy for Malignant Pleural Mesothelioma: Final Results With Long-term Follow-up. International Journal of Radiation Oncology Biology Physics, 2013, 87, S114.	0.4	0
30	Plasmatic Cytokine Levels in Lung Cancer Patients Undergoing Definitive Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 87, S513.	0.4	0
31	Concurrent chemoradiotherapy with tomotherapy in locally advanced non-small cell lung cancer: a phase i, docetaxel dose-escalation study, with hypofractionated radiation regimen. BMC Cancer, 2013, 13, 513.	1.1	16
32	Tomotherapy after Pleurectomy or Decortication or Biopsy for Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2013, 8, e50-e51.	0.5	2
33	Tomotherapy after Pleurectomy/Decortication or Biopsy for Malignant Pleural Mesothelioma Allows the Delivery of High Dose of Radiation in Patients with Intact Lung. Journal of Thoracic Oncology, 2012, 7, 1862-1866.	0.5	53
34	High-dose Radiation Therapy Delivered With Tomotherapy to the Intact Lung for Malignant Pleural Mesothelioma. International Journal of Radiation Oncology Biology Physics, 2012, 84, S155.	0.4	0
35	Tomotherapy After Pleurectomy/decortication For Malignant Pleural Mesothelioma Allows The Delivery Of Full Dose Of Radiation In Patients With Intact Lung. International Journal of Radiation Oncology Biology Physics, 2011, 81, S598-S599.	0.4	0
36	Intensity-modulated radiotherapy (IMRT)/Tomotherapy following neoadjuvant chemotherapy in stage IIB–IVA/B undifferentiated nasopharyngeal carcinomas (UCNT): A mono-institutional experience. Oral Oncology, 2011, 47, 905-909.	0.8	6

3

#	Article	IF	CITATIONS
37	Helical Tomotherapy in Children and Adolescents: Dosimetric Comparisons, Opportunities and Issues. Cancers, 2011, 3, 3972-3990.	1.7	10
38	Treatment of recurrent high-grade gliomas with GliaSite brachytherapy: a prospective mono-institutional Italian experience. Tumori, 2011, 97, 614-9.	0.6	9
39	Postoperative reduced dose of cisplatin concomitant with radiation therapy in high―risk head and neck squamous cell carcinoma. Cancer, 2009, 115, 2464-2471.	2.0	13
40	Organ preservation in locally advanced head and neck cancer of the larynx using induction chemotherapy followed by improved radiation schemes. European Archives of Oto-Rhino-Laryngology, 2009, 266, 719-726.	0.8	10
41	Neoadjuvant accelerated chemotherapy followed by hyperfractionated radiation therapy in patients with operable, locally advanced head and neck carcinoma. Oral Oncology, 2005, 41, 526-533.	0.8	10
42	Radiotherapy for patients with early-stage glottic carcinoma. Cancer, 2003, 98, 765-772.	2.0	80
43	Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy—a multicenter randomized trial. International Journal of Radiation Oncology Biology Physics, 2003, 55, 78-92.	0.4	112
44	Squamous cell carcinoma of the hypopharynx treated with surgery and radiotherapy. Journal of Laryngology and Otology, 2002, 116, 24-8.	0.4	15
45	Nasopharyngeal cancer WHO type II-III: monoinstitutional retrospective analysis with standard and accelerated hyperfractionated radiation therapy. Oral Oncology, 2002, 38, 137-144.	0.8	11
46	Changes in presentation and survival of head and neck carcinomas in Northeastern Italy, 1975-1998. Cancer, 2002, 95, 540-552.	2.0	13
47	Ocular metastases from breast carcinoma: A multicentric retrospective study Oncology Reports, 2000, 7, 761-5.	1.2	35
48	ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer (EORTC). Radiotherapy and Oncology, 2000, 55, 111-119.	0.3	53
49	The effect of granulocyte colony-stimulating factor on oral mucositis in head and neck cancer patients treated with hyperfractionated radiotherapy. Oral Oncology, 1999, 35, 203-208.	0.8	30
50	Radiation treatment of glottic squamous cell carcinoma, stage I and II: Analysis of factors affecting prognosis. International Journal of Radiation Oncology Biology Physics, 1998, 40, 541-548.	0.4	37
51	Combined radiotherapy and bleomycin in patients with inoperable head and neck cancer with unfavourable prognostic factors and severe symptoms. Oral Oncology, 1998, 34, 119-122.	0.8	25
52	Kaposi's Sarcoma in a Heart Transplant Patient. Acta Oncológica, 1998, 37, 769-770.	0.8	2
53	Combined Modality Treatment of Locally Advanced Lung Cancer. Tumori, 1998, 84, 259-269.	0.6	3
54	Post-operative adjuvant therapy for non-small-cell lung cancer. Lung Cancer, 1997, 17, S23-S25.	0.9	8

#	Article	IF	CITATIONS
55	Variations in Tumor Levels of Cis-Platinum through a Course of Fractionated Radiotherapy in Patients with Non-Small Cell Lung Cancer. Tumori, 1997, 83, 904-906.	0.6	O
56	Squamous cell carcinoma of the posterior pharyngeal wall: characteristics compared with the lateral wall. Journal of Laryngology and Otology, 1995, 109, 120-125.	0.4	13
57	Simultaneous radiochemotherapy in the treatment of inoperable, locally advanced head and neck cancers. A single-institution study. Cancer, 1995, 75, 1025-1029.	2.0	10
58	The efficacy of radiotherapy in the treatment of intraocular metastases. British Journal of Radiology, 1993, 66, 699-702.	1.0	31
59	Radiotherapy enhanced by cis-platinum in stage III non-small cell lung cancer: a phase II study. Radiotherapy and Oncology, 1992, 23, 241-244.	0.3	17
60	Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. International Journal of Radiation Oncology Biology Physics, 1992, 24, 11-15.	0.4	174
61	Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. International Journal of Radiation Oncology Biology Physics, 1992, 24, 573-574.	0.4	10
62	Whole abdomen radiation therapy after a short chemotherapy course and second-look laparotomy in advanced ovarian cancer. Gynecologic Oncology, 1991, 41, 206-211.	0.6	7
63	Radiation Therapy Combined with Chemotherapy for Inoperable Pancreatic Carcinoma. Tumori, 1991, 77, 61-64.	0.6	18
64	Combined radiotherapy and chemotherapy versus radiotherapy alone in locally advanced epidermoid bronchogenic carcinoma a randomized study. Cancer, 1990, 65, 400-404.	2.0	90
65	Postoperative Radiotherapy in Locally Advanced Head and Neck Cancer. Tumori, 1989, 75, 47-52.	0.6	7
66	Multiple fraction per day radiation therapy for inoperable esophageal cancer. International Journal of Radiation Oncology Biology Physics, 1988, 14, 855-860.	0.4	17
67	Accelerated split course regimen in the treatment of brain metastases. Radiotherapy and Oncology, 1988, 12, 39-44.	0.3	12
68	Thoracic radiation therapy and concomitant low-dose daily paclitaxel in non-small cell lung cancer: A phase I study. Oncology Reports, 0, , .	1.2	3